Combining TGF-ß Inhibition with Radiation Therapy for Inoperable Keloids
Our research aims to improve treatment for keloid tumors by combining radiation with a TGF-ß inhibitor, a type of drug that prevents the build-up of collagen, a key component of wound healing. A keloid is a raised scar that grows larger than the wound that caused it due to an excess of collagen and can be painful and have social, emotional and economic impacts on the patient. Current treatments include compression devices, injections and surgery, but despite these interventions, keloids can worsen to the point of severe pain and dysfunction. Radiation therapy (RT) is the primary treatment for keloids that cannot be surgically removed, but a variety of concerns about using RT on large keloids exist. Our multi-institutional team is conducting a clinical trial to determine the safety and efficacy of various combinations of the TGF-ß inhibitor applied to the keloid as a gel and RT doses. We aim to show that this innovative combination treatment will improve response rates, enhance healing and cosmetic outcomes and result in more patients with keloids benefitting from RT.
